Skip to content

Transnasal Humidified Rapid Insufflation System for Intubation

Effect of Transnasal Humidified Rapid Insufflation Ventilator Exchange During Anesthesia Induction With Double Lumen Endotracheal Tube

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04238351
Enrollment
80
Registered
2020-01-23
Start date
2020-02-25
Completion date
2020-12-31
Last updated
2020-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxemia

Brief summary

Transnasal humidified rapid insufflation ventilator exchange (THRIVE) or not during the anesthesia induction

Detailed description

Control group-usual mask ventilation during apnea for anesthetic intubation and check tube positioning THRIVE group-applying THRIVE during apnea for anesthetic intubation and check tube positioning

Interventions

DEVICETransnasal humidified rapid insufflation ventilator exchange

applying 40L of oxygen for 1min and afte that increase oxygen flow up to 70L for 1 min.

DEVICEConventional face mask

applying oxygen using usual face mask

Sponsors

Gachon University Gil Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Participants, care giver and outcome assessor can not know the group assingment.

Intervention model description

Applying Transnasal humidified rapid insufflation ventilator exchange

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients who scheduled for elective lung surery with one lung ventilation

Exclusion criteria

* suspicious difficult intubation (BMI \>35kg/m2, mouth opening \< 3 finger, Mallampati G \>3), Room air SpO2 \< 90%, active pulmonary infection, emergency operation, pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Desaturationduring the anesthesia inducitonnumber of patients who experienced SpO2 under 93%

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026